search:rituximab單株抗體相關網頁資料

- www2.cmu.edu.tw
  
  單株抗體
  
  這樣的想法直到“單株抗體”﹝Monoclonal Antibodies. (MAbs)﹞ .... 這種經由基因工程改造的小鼠其製造抗體的基因已經由.
  
  2025-05-20
  
  瀏覽：1016
- en.wikipedia.org
  
  Rituximab - Wikipedia, the free encyclopedia
  
  Rituximab (trade names Rituxan, MabThera and Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells.
  
  2025-05-21
  
  瀏覽：1001

rituximab單株抗體的相關文章

rituximab單株抗體的相關公司資訊

rituximab單株抗體的相關商品

Rituximab, an Anti-CD20 Monoclonal Antibody: History & Mechanism

日期：2025-05-16

Rituximab, a chimeric murine/human monoclonal antibody, approved in the United States only for the treatment of refractory or relapsed B-cell lymphomas, reacts with the CD20 antigen (Figure 1). [8] It contains the complementarity determining regions of th...

全文

Rituxan Herceptin

日期：2025-05-19

因此在1997年，Rituxan被研發出來當治療非何杰金氏淋巴瘤單株抗體新藥。在美國，Rituxan是第一個被允許用來治療癌症 ......

全文

單株抗體用於多發性硬化症之治療 - 中華民國藥師公會全國聯合會

日期：2025-05-14

2011年6月30日 ... 關鍵字：多發性硬化症、單株抗體 ... 代表藥物例如rituximab (Rituxan) 和basiliximab (Simulect)，嵌合單株抗體通常 ... 完全人類單株抗體(fully human mAbs，100%人類，藥名以mumab 結尾) ......

全文

Rituximab, an Anti-CD20 Monoclonal Antibody: History & Mechanism: Mechanism of Action

日期：2025-05-16

Mechanism of Action While rituximab has been used in the various indications, with the exception of lymphoma where the target lymphoma cells are actually eliminated by rituximab, it is not entirely clear that rituximab was responsible for the improvement ...

全文

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of pat

日期：2025-05-19

1. J Clin Oncol. 1998 Aug;16(8):2825-33. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. McLaughlin P(1), Grillo-López AJ, Link BK, Levy R, Czuczman MS ......

全文

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte c

日期：2025-05-16

1. Blood. 1999 Oct 1;94(7):2217-24. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Winkler U, Jensen M, Manzke O ......

全文

Rituximab - National Cancer Institute

日期：2025-05-17

This page contains brief information about rituximab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. ... Rituximab (rih-TUK-sih-mab) This page contains brief information about rituxi...

全文

Rituximab - WebMD - Better information. Better health.

日期：2025-05-19

Rituximab is available for intravenous (IV) use. How It Works Rituximab belongs to a group of medicines known as monoclonal antibodies. It is designed to recognize specific proteins that are found on the surface of some lymphoma cells. The monoclonal anti...

全文

12 > »